NCT03732391View on ClinicalTrials.gov

Phase 2 Study of Pembrolizumab+Carboplatin in Breast Related Cancer Antigens-related Metastatic Breast Cancer (PEMBRACA)

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

December 12, 2018

Primary Completion Date

June 30, 2022

Study Completion Date

January 30, 2023

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Pembrolizumab 25 MG(milligram)/ML

Carboplatin AUC6 EV will be given every 3 weeks in combination with Pembrolizumab 200 mg EV every 3 weeks for 6 cycles. Afterwards, the Pembrolizumab will be continued with the same schedule until unacceptable toxicity or disease progression

Trial Locations (1)

41125

AOU Modena, Modena

All Listed Sponsors
lead

CORTESI LAURA

OTHER

NCT03732391 - Phase 2 Study of Pembrolizumab+Carboplatin in Breast Related Cancer Antigens-related Metastatic Breast Cancer (PEMBRACA) | Biotech Hunter | Biotech Hunter